Cardiol Therapeutics (TSE:CRDL) Shares Down 14.6% – Here’s Why

Shares of Cardiol Therapeutics Inc. (TSE:CRDL) were down 14.6% during trading on Monday . The company traded as low as C$1.24 and last traded at C$1.29. Approximately 551,069 shares traded hands during mid-day trading, an increase of 406% from the average daily volume of 108,983 shares. The stock had previously closed at C$1.51.

Cardiol Therapeutics Stock Performance

The firm’s 50-day simple moving average is C$1.50 and its two-hundred day simple moving average is C$1.65. The company has a current ratio of 2.49, a quick ratio of 6.84 and a debt-to-equity ratio of 1.59. The company has a market cap of C$129.00 million, a PE ratio of -3.15 and a beta of 1.31.

Cardiol Therapeutics (TSE:CRDL) last released its earnings results on Thursday, November 13th. The company reported C($0.12) earnings per share (EPS) for the quarter. As a group, research analysts anticipate that Cardiol Therapeutics Inc. will post -0.49 earnings per share for the current fiscal year.

About Cardiol Therapeutics

Cardiol Therapeutics Inc (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.